Shares of Cytori Therapeutics (CYTX) are currently a strong buy around the $5 level, ahead of near-term commercialization of its adult-derived adipose stem cell banking in Japan (StemSource) and breast reconstruction applications (Celution System) in Europe. Cytori has traded in a sawtooth pattern over the last 52 weeks with reliable bounces from the $5 level to over $6 on several previous occasions. Despite concerns by some investors over a possible stock offering to shore up the balance sheet, I believe this can be avoided. Cytori has non-dilutive means to raise money, including the sale of its non-core biosurgery division Japan Thin Film for $15 - $20 million and a likely deal with Olympus Corp to develop a therapeutic application for the Celution System in the treatment of GI fistulas with an estimated up-front payment of $10 million. See my most recent Seeking Alpha article or research reports on CYTX for more details
Did you like this article?
Submitted By 
's
